The aim of this review is to address the role of AGE, RAGE, and sRAGE as pathogenetic, diagnostic, and prognostic molecules in obesity and obesity-related CVD, as well as to describe available strategies for reducing AGE–RAGE system activation and the associated beneficial effects. This evidence concerns the gene AGER and obesity disorder.